Novo says study shows Levemir reduces body weight

Denmark’s Novo Nordisk, the world’s biggest maker of insulin, said on Tuesday a new study showed its long-acting insulin Levemir reduces body weight and improves blood glucose levels in type 2 diabetes patients.

The new data, a subanalysis of 2,377 patients from a larger multinational study, indicated that individuals taking Levemir lost 0.7 kilograms after 14 weeks, compared to a baseline.

“The weight loss was more pronounced in those who entered the trial at higher weight,” Novo said in a statement.

The data was presented on Tuesday at the world congress of the International Diabetes Federation in Capetown, South Africa.

Print Version
Tell-a-Friend comments powered by Disqus

RELATED ARTICLES:

Don’t Blame Breast Density; $$$ Toxicity; ‘Nurse Ratched’ Returns   Early Heart Data Look Good for Obesity Drug   Sexual function dramatically improves in women following bariatric surgery, Penn study finds   Glowing fish shed light on metabolism   Gastric bypass for weight loss increases alcohol use, study says   Obesity Costs Twice as Much   Patients with diabetes may need fewer medications after bariatric surgery   Sleep problems linked to weight gain in middle-age   Community interventions and in-home visits may slow excess weight gain in American Indian children   Eating Breakfast Boosts Weight Loss   Obesity May be Evaded by Weight Loss Surgery   Vitamin D, Weight Loss, and Obesity